[Skip to Navigation]
December 1996

Calcipotriene Ointment Applied Once a Day for Psoriasis: A Double-Blind, Multicenter, Placebo-Controlled Study

Author Affiliations

Eastern Virginia Medical School 601 Medical Tower Norfolk, VA 23507

Cincinnati, Ohio

New York, NY

Buffalo, NY

Evansville, Ind

Madison, Wis

Indianapolis, Ind

Chicago, Ill

Arch Dermatol. 1996;132(12):1527. doi:10.1001/archderm.1996.03890360121033

Clinical experience with calcipotriene has shown its efficacy in the treatment of psoriasis, both alone1-5 and in combination with other agents. This double-blind, placebo-controlled study was designed to provide clinical experience in the United States with once-daily treatment of plaque-type psoriasis with 0.005% calcipotriene ointment.

Patients and Methods.  Two hundred thirty-five otherwise healthy nonpregnant patients, aged 18 to 86 years (mean, 45.1 years), with stable plaque-type psoriasis covering 5% to 20% of skin surface and showing plaque elevation of at least 4 on a 9-point scale, were entered into a randomized, double-blind, clinical trial of 0.005% calcipotriene ointment applied once a day for 8 weeks. Scaling, erythema, plaque elevation, and physician's global assessment were scored on a 9-point scale. Patients were evaluated at baseline and at weeks 1, 2, 4, 6, and 8 of treatment (Figure 1).

Results.  Forty percent of patients treated with the active drug and 2.2%

Add or change institution